Literature DB >> 23595854

[Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy].

S Bölükbas1, J Schirren.   

Abstract

The role of surgical resection per se and the type of surgery in the management of multimodality treated malignant pleural mesothelioma remains controversial. Patient selection for either extrapleural pneumonectomy or radical pleurectomy depends not only on the cardiopulmonary status of the patient, tumor stage and intraoperative findings but is also strongly influenced by surgeons' preference, experience and philosophy. The aim of this review is to compare extrapleural pneumonectomy and radical pleurectomy with regard to surgical technique, morbidity, mortality and survival.

Entities:  

Mesh:

Year:  2013        PMID: 23595854     DOI: 10.1007/s00104-012-2432-5

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  30 in total

1.  Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.

Authors:  Loïc Lang-Lazdunski; Andrea Bille; Rohit Lal; Paul Cane; Emma McLean; David Landau; Jeremy Steele; James Spicer
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.

Authors:  Martin Utley; Francesca Fiorentino; Tom Treasure
Journal:  Eur J Cardiothorac Surg       Date:  2010-03-30       Impact factor: 4.191

3.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

4.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Authors:  C Manegold; J Symanowski; U Gatzemeier; M Reck; J von Pawel; C Kortsik; K Nackaerts; P Lianes; N J Vogelzang
Journal:  Ann Oncol       Date:  2005-04-11       Impact factor: 32.976

5.  Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg; Melissa J Culligan; Rosemarie Mick; James Stevenson; Stephen M Hahn; Daniel Sterman; Salman Punekar; Eli Glatstein; Keith Cengel
Journal:  Ann Thorac Surg       Date:  2012-05       Impact factor: 4.330

6.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors:  V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

7.  Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.

Authors:  Michael Ried; Tobias Potzger; Nico Braune; Reiner Neu; York Zausig; Berthold Schalke; Claudius Diez; Hans-Stefan Hofmann
Journal:  Eur J Cardiothorac Surg       Date:  2012-08-10       Impact factor: 4.191

8.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Authors:  Jacek Jassem; Rodryg Ramlau; Armando Santoro; Wolfgang Schuette; Assad Chemaissani; Shengyan Hong; Johannes Blatter; Susumu Adachi; Axel Hanauske; Christian Manegold
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

9.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

10.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

View more
  4 in total

1.  In reply.

Authors:  Volker Neumann; Stefan Löseke; Dennis Nowak; Felix J F Herth
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

2.  Surgical therapeutic options.

Authors:  Servet Bölükbas; Joachim Schirren
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

Review 3.  Role of microRNAs in malignant mesothelioma.

Authors:  A Truini; S Coco; A Alama; C Genova; C Sini; M G Dal Bello; G Barletta; E Rijavec; G Burrafato; F Boccardo; F Grossi
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

4.  Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.

Authors:  Kwan-Chang Kim; Hong-Phuc Vo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.